More Herceptin Biosimilars Move In, But Roche Thinks It Can Stand Its Ground

Two biosimilar versions of Roche's blockbuster cancer therapy Herceptin reported positive Phase III bioequivalence data at ASCO – setting up for regulatory approvals in Europe, the US and Japan soon.